Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

In the Media

  • July 3, 2022

What are cannabinoid analogs?

Cannabinoid analogs are novel cannabinoid compounds that are slightly modified from the naturally occurring cannabinoids in the plant. Since they have a new molecular structure that hasn’t previously existed, they are recognized as new chemical entities (NCEs). InMed’s CEO, Eric A. Adams, gives an example of a cannabinoid analog and explains how these new chemical entities are patentable. Natural cannabinoids isolated from the plant are not patentable.

Why pursue cannabinoid analogs?
Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:

  • Targeting certain physiological outcomes in specific diseases;
  • Improving upon the safety profile of the natural cannabinoids;
  • Enhancing the ability to integrate with specific delivery technologies; and
  • Protecting the long-term research investment and commercial opportunities.

InMed’s subsidiary, BayMedica, has developed a library of patentable cannabinoid analogs. Learn more about our novel cannabinoid analogs.

 

Full Article

Share this post

Latest Articles

How Could a Change in Legislation Affect the Cannabinoid Industry?

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how a change in legislation could impact the bioidentical cannabinoid manufacturing industry. In this interview,

Read More
May 16, 2023

BayMedica’s Bioidentical Rare Cannabinoids Fill a Market Need for Large Scale Batch-to-batch Consistency

InMed’s VP, Sales & Marketing, Jerry P. Griffin, talks about how the market for bioidentical rare cannabinoids has changed over the past year. Jerry contributes

Read More
May 8, 2023

The Dales Report: InMed’s Latest Milestones Explained

InMed CEO, Eric A. Adams, joins Shadd Dales of The Dales Report to speak about InMed’s latest milestones including the latest on the Phase 2

Read More
April 19, 2023
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent